---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-007420"
form_type: "8-K"
ticker: "APYX"
cik: "0000719135"
company_name: "Apyx Medical Corp"
filed_at: "2026-03-10T23:59:59+00:00"
generated_at: "2026-05-15T17:18:14.353372+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Apyx Medical Q4 revenue record $19.2M, net loss narrows; FY2026 guidance $57.5-58.5M

## Summary
- Q4 total revenue record $19.2M, +34.7% YoY; Surgical Aesthetics +38.1% to $16.7M driven by AYON launch.
- Q4 net loss narrowed to $1.3M ($0.03/sh) from $4.6M ($0.12/sh); Adjusted EBITDA $0.7M vs ($2.2M).
- FY2025 total revenue $52.8M (+9.9% YoY); net loss $11.2M ($0.27/sh) vs $23.5M ($0.66/sh) in 2024.
- FY2026 guidance: total revenue $57.5M-$58.5M; Surgical Aesthetics rev $53M-$54M; OEM rev ~$4.5M.
- Submitted 510(k) for AYON power liposuction label expansion; clearance anticipated mid-2026.

## SEC filing metadata
- accession: 0001437749-26-007420
- form_type: 8-K
- ticker: APYX
- cik: 0000719135
- company_name: Apyx Medical Corp
- filed_at: 2026-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/719135/000143774926007420/0001437749-26-007420-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/719135/000143774926007420/apyx20250930_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-007420
- JSON: https://secwatch.observer/filing/0001437749-26-007420.json
- Plain text: https://secwatch.observer/filing/0001437749-26-007420.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.